Диссертация (1140465), страница 21
Текст из файла (страница 21)
Shield, G. Gmel, et al. // Eur. Neuropsychopharmacol. – 2013. – Vol. 23. – P.89-97.12618. Rehm, J. Global burden of alcoholic liver diseases [Text] / J. Rehm,A.V. Samokhvalov, K.D. Shield // J. Hepatol. – 2013. – Vol. 59. – P. 160-168.19. Stikel, F. Pathophysiology and management of alcoholic liver disease:update 2016 [Text] / F.
Stickel, C. Datz, J. Hampe, and R. Bataller // Gut and Liver. – 2017. – Vol. 11, No. 2. – P. 173-188.20. Leon, D.A. Liver cirrhosis mortality rates in Britain from 1950 to 2002:an analysis of routine data [Text] / D.A. Leon, J. McCambridge // Lancet. – 2006.– Vol. 367. – P. 52-56. 21. Case, A. Rising morbidity and mortality in midlife among white nonHispanic Americans in the 21st century [Text] / A. Case, A. Deaton // Proc.
Natl.Acad. Sci. U. S. A.– 2015. – Vol. 112. – P. 15078-15083. 22. Yadav, D. The epidemiology of pancreatitis and pancreatic cancer [Text]/ D. Yadav, A.B.Lowenfels // Gastroenterology. – 2013. – Vol. 144. – P. 12521261.23. Comorbidity of fetal alcohol spectrum disorder: a systematic review andmeta-analysis [Text] / S. Popova, S. Lange, K.
Shield, et al. // Lancet. – 2016. –Vol. 387. – P. 978-987. 24. Seitz, H.K. Molecular mechanisms of alcohol-mediated carcinogenesis[Text] / H.K. Seitz, F. Stickel // Nat. Rev. Cancer. – 2007. – Vol. 7. – P. 599-612. 25. Fernández-Solà, J. Cardiovascular risks and benefits of moderate andheavy alcohol consumption [Text] / J. Fernández-Solà // Nat.
Rev. Cardiol. – 2015.– Vol. 12. – P. 576-587. 26. Depression in patients with alcohol use disorders: systematic review andmeta-analysis of outcomes for independent and substance-induced disorders [Text]/ J.A. Foulds, S.J. Adamson, J.M. Boden, et al. //J.
Affect. Disord. – 2015. – Vol.185. – P. 47-59. 27. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis [Text] / A.A. Mokdad, A.D. Lopez, S. Shahraz, et al. // BMCMed. – 2014. – Vol. 12. – P. 145.12728.World Health Organization. Global health estimates (GEHE) 2014: YLLby age, sex and cause [Text]. Geneva: World Health Organization, 2012. 29. World Health Organization.
WHO mortality database: raw data files[Text]. Geneva: World Health Organization, 2015.30. Sheron, N. Alcohol and liver disease in Europe: simple measures havethe potential to prevent tens of thousands of premature deaths [Text] / N. Sheron //J. Hepatol. – 2016. – Vol. 64. – P. 957-967.31.
Liver transplantation for alcoholic liver disease in Europe: a study fromthe ELTR (European Liver Transplant Registry) [Text] / P. Burra, M. Senzolo, R.Adam, et al. //Am. J. Transplant. – 2010. – Vol. 10. – P. 138-148.32. Sheron, N. Projections of alcohol deaths: a wake-up call [Text] / N.Sheron, C. Hawkey, I. Gilmore // Lancet.
– 2011. – Vol. 377. – P. 1297-1299.33. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver [Text] / M.R. Teli, C.P. Day, A.D. Burt et al. // Lancet. – 1995. – Vol. 346.– P. 987-990.34. Stickel, F. Alcoholic cirrhosis and hepatocellular carcinoma [Text] / F.Stikel // Adv.
Exp. Med. Biol.– 2015. – Vol. 815. – P. 113-130.35. Konishi, M. Role of microsomal enzymes in development of alcoholicliver diseases [Text] / M. Konishi, H. Ishii // J. Gastroenterol.Hepatol. – 2007. –Vol. 22, Suppl. 1. – S7-S10.36. Dynamics of cytochrome P4502E1 activity in man: induction by ethanoland disappearance during withdrawal phase [Text] / C.M. Oneta, C.S. Lieber, J. Li,et al.
//J. Hepatol.– 2002. – Vol. 36. – P. 47-52.37. Alcoholic liver disease: clinical and translational research [Text] / M.G.Neuman, S. Malnick, Y. Maor, et al. // Exp. Mol. Pathol. – 2015. – Vol. 99. – P.596-610.38. Inhibition of ethanol-induced liver disease in the intragastric feeding ratmodel by chlormethiazole [Text] / Z. Gouillon, D. Lucas, J.
Li, et al. //Proc. Soc.Exp. Biol. Med.– 2000. – Vol. 224. – P. 302-308.12839. Cytochrome P450 CYP2E1, but not nicotinamide adenine dinucleotidephosphate oxidase, is required for ethanol-induced oxidative DNA damage in rodent liver [Text] / B.U. Bradford, H. Kono, F. Isayama, et al. //Hepatology. – 2005.– Vol. 41. – P. 336-344.40. European Code against Cancer 4th Edition: alcohol drinking and cancer[Text] / C. Scoccianti, M. Cecchini, A.S. Anderson, et al.
//Cancer Epidemiol. –2015. – Vol. 39, Suppl. 1. – S67-S74.41. Gao, B. Alcoholic liver disease: pathogenesis and new therapeutic targets [Text] / B.Gao, R.Bataller // Gastroenterology. – 2011. – Vol. 141. – P. 15721585.42. Brunt, E.M. Fatty liver disease: alcoholic and non-alcoholic [Text] /E.M. Brunt, B.A. Neuschwander-Tetri, A.D. Burt // In: Burt A, Portmann B, Ferrell L, eds. MacSween’s pathology of the liver. 6th ed. Edinburgh: Churchill Livingstone, 2012.
– P. 293-360.43. TLR2 and TLR9 contribute to alcohol-mediated liver injury through induction of CXCL1 and neutrophil infiltration [Text] / Y.S. Roh, B. Zhang, R.Loomba, E. Seki // Am. J. Physiol. Gastrointest.Liver.Physiol. – 2015. – Vol. 309.– G30-G41.44. An, L. Cytokines in alcoholic liver disease [Text] / L. An, X. Wang, A.I.Cederbaum // Arch.
Toxicol. – 2012. – Vol. 86. – P. 1337-1348.45. Petrasek, J. Toll-like receptors in liver disease [Text] / J. Petrasek, T.Csak, G. Szabo // Adv. Clin.Chem. – 2013. – Vol. 59. – P. 155-201.46. The interleukin-17 pathway is involved in human alcoholic liver disease[Text] / A. Lemmers, C. Moreno, T. Gustot, et al. // Hepatology. – 2009.
– Vol. 49.– P. 646-657.47. Szabo, G. Inflammasome activation and function in liver disease [Text] /G. Szabo, J. Petrasek // Nat. Rev. Gastroenterol.Hepatol. – 2015. – Vol. 12. – P.387-400.12948. Schuppan, D. Liver fibrosis: common mechanisms and antifibrotic therapies [Text] / D. Schuppan// Clin. Res. Hepatol.Gastroenterol. – 2015. – Vol. 39,Suppl. 1. – S51-S59.
49. Early response of alpha-2(I) collagen to acetaldehyde in human hepaticstellate cells is TGF-beta independent [Text] / G. Svegliati-Baroni, Y. Inagaki,A.R. Rincon-Sanchez, et al. // Hepatology. – 2005. – Vol. 42. – P. 343-352. 50. NADPH oxidase signal transduces angiotensin II in hepatic stellate cellsand is critical in hepatic fibrosis [Text] / R. Bataller, R.F. Schwabe, Y.H. Choi, etal.
// J. Clin. Invest. – 2003. – Vol. 112. – P. 1383-1394. 51. Competitive inhibition of leptin signaling results in amelioration of liverfibrosis through modulation of stellate cell function [Text] / E. Elinav, M. Ali, R.Bruck, et al. //Hepatology.
– 2009. – Vol. 49. – P. 278-286. 52. Cannabinoid receptor type I modulates alcohol-induced liver fibrosis[Text] / E. Patsenker, M. Stoll, G. Millonig, et al. // Mol. Med. – 2011. – Vol. 17. –P. 1285-1294. 53. 4-Hydroxynonenal as a selective profibrogenic stimulus for activatedhuman hepatic stellate cells [Text] / E. Zamara, E. Novo, F. Marra, et al.
// J. Hepatol. – 2004. – Vol. 40. – P. 60-68. 54. Hepatocellular carcinoma in cirrhosis: incidence and risk factors [Text] /G. Fattovich, T. Stroffolini, I. Zagni, F. Donato // Gastroenterology. – 2004. – Vol.127, Suppl. 1. – S35-S50. 55. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma [Text] / A. Villanueva, A. Portela, S. Sayols, et al. // Hepatology. – 2015. –Vol. 61. – P. 1945-1956. 56. Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis [Text] / L. Dubuquoy, A.
Louvet, G. Lassailly, et al. // Gut. – 2015. – Vol. 64. – P. 1949-1960.13057. Hepatic cell proliferation plays a pivotal role in the prognosis of alcoholic hepatitis [Text] / N. Lanthier, L. Rubbia-Brandt, N. Lin-Marq, et al. // J. Hepatol. – 2015. – Vol. 63. – P. 609-621. 58. Liver progenitor cell markers correlate with liver damage and predictshort-term mortality in patients with alcoholic hepatitis [Text] / P.
Sancho-Bru, J.Altamirano, D. Rodrigo-Torres, et al. // Hepatology. – 2012. – Vol. 55. – P. 19311941.59. Animals models of gastrointestinal and liver diseases. Animal models ofalcohol-induced liver disease: pathophysiology, translational relevance, and challenges [Text] / S. Mathews, M. Xu, H. Wang, A. Bertola, B. Gao// Am. J.
Physiol.Gastrointest.Liver Physiol. – 2014. – Vol. 306. – G819-G823. 60. Alcoholic hepatitis: translational approaches to develop targeted therapies [Text] / P. Mandrekar, R. Bataller, H. Tsukamoto, B. Gao // Hepatology. –2016. – Vol. 64. – P. 1343-1355. 61. Models of alcoholic liver disease in rodents: a critical evaluation [Text] /P. de la M Hall, C.S. Lieber, L.M. DeCarli, et al. // Alcohol.Clin. Exp.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
